

Assessing the safety and effectiveness of a biopsy instrument when sampling tumours in the urinary bladder

Submission date 30/07/2020	Recruitment status Stopped	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 10/09/2020	Overall study status Stopped	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 25/09/2025	Condition category Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Muscle-invasive bladder cancer is cancer that has spread into the muscle wall of the bladder. Treatment is based on taking a biopsy (sample) of the tumor. Today a biopsy is retrieved by a surgical procedure called transurethral resection under anesthetic before treatment with either neoadjuvant chemotherapy (drug treatment) and cystectomy (removal of the bladder) or cystectomy only. The aim of this study is to investigate a new biopsy device (Urodrill) for diagnosing muscle-invasive bladder cancer under local anesthetic.

Who can participate?

Patients aged 18 and over with suspected muscle-invasive bladder cancer

What does the study involve?

Participants are randomly allocated to undergo either standard transurethral resection or an endoscopic biopsy under local anesthetic with the Urodrill instrument.

What are the possible benefits and risks of participating?

The benefit from participating is a chance to avoid a transurethral resection of the bladder tumor under anesthetic and instead have a local anesthetic procedure in the outpatient clinic. The risks are related to biopsying the tumor in the conventional and experimental group mainly relating to bleeding after the procedure and perforation.

Where is the study run from?

Skåne University Hospital (Sweden)

When is the study starting and how long is it expected to run for?

November 2019 to June 2026

Who is funding the study?

Skåne Region Health Care Fund for Development and Innovation (Sweden)

Who is the main contact?
Prof. Fredrik Liedberg
fredrik.liedberg@med.lu.se

Contact information

Type(s)
Scientific

Contact name
Prof Fredrik Liedberg

ORCID ID
<https://orcid.org/0000-0001-8193-0370>

Contact details
Department of Urology
Lund University
Skåne University Hospital
Jan Waldenströmsgata 5
Malmö
Sweden
SE-205 02
+46 (0)40 33 19 41
fredrik.liedberg@med.lu.se

Additional identifiers

Clinical Trials Information System (CTIS)
Nil known

Protocol serial number
CIV-20-05-032908

Study information

Scientific Title
Safety and efficacy of the EndoDrill® Uro X biopsy instrument when sampling tumours in the urinary bladder

Acronym
Urodrill study

Study objectives
Time from radiological suspicion to start of definitive treatment for muscle-invasive bladder cancer can be decreased by using the Urodrill pathway.

Ethics approval required
Old ethics approval format

Ethics approval(s)

Approved 18/03/2020, National Ethical Committee (Etikprövningsmyndigheten, Box 2110, 750 02 Uppsala, Sweden; +46 (0)10 475 08 00; registrator@etikprovning.se), ref: 2019-06537

Study design

Randomized controlled trial

Primary study design

Interventional

Study type(s)

Diagnostic

Health condition(s) or problem(s) studied

Bladder cancer

Interventions

Method of randomisation: closed envelopes

Conventional arm: standard transurethral resection

Experimental arm: endoscopic biopsy under local anesthesia with the Urodrill instrument

Intervention Type

Procedure/Surgery

Primary outcome(s)

Time from radiological suspicion of MIBC to start of definitive treatment for MIBC (neoadjuvant chemotherapy and/or cystectomy): measured using prospective registration at day for radiological report stating suspicion of MIBC to starting day of neoadjuvant chemotherapy, or cystectomy for those operated without neoadjuvant chemotherapy by prospective registration

Key secondary outcome(s)

1. Complications from the EndoDrill biopsy procedure assessed by a structured telephone interview 2 weeks after the procedure
2. Proportion of patients with MIBC that the EndoDrill® Uro X -instrument failed to detect, but diagnosed with ordinary TURBT, measured using pathology at [at secondary procedure with TURBT for those in the experimental arm without verification of MIBC and with MIBC verified by TURBT
3. Proportion of patients with successful molecular classification based on RNA sequencing performed in real time with 6 weeks of sampling in both arms
4. Cancer-specific survival (CSS) measured using chart review at 24 months after initiating definitive treatment for MIBC
5. Overall proportion of patients who correctly followed the protocol and were staged as MIBC in the intervention arm, measured using chart review within 3 months of inclusion
6. Cost-effectiveness based on EQ5D5L at baseline and 2 weeks
7. Quality of life measured using FACT-G questionnaire preoperatively and FACT-VCI at 12 months
8. Adverse events assessed during a phone interview by a research nurse 2 weeks after the procedures
9. Sensitivity and specificity for CT-urography and MRI respectively to accurately determine

muscle-invasive bladder cancer compared to the outcome of the combined measure of biopsy and cystectomy specimen, measured using sensitivity calculations compared to pathology within 3 months of inclusion

Completion date

30/06/2026

Reason abandoned (if study stopped)

Objectives no longer viable

Eligibility

Key inclusion criteria

1. Provision of written informed consent
2. ≥ 18 years of age
3. Patients attending participating urology departments for haematuria investigation and CT-urography suspicious of muscle-invasive bladder cancer

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Patients unable or unwilling to undergo EndoDrill biopsy
2. Bleeding diathesis prohibiting EndoDrill biopsies
3. Ongoing immunosuppression (except corticosteroids in moderate doses, less than 10 mg prednisolone or equivalent daily)
4. Patients not suitable/fit for radical treatment for MIBC
5. Pregnancy

Date of first enrolment

01/10/2020

Date of final enrolment

30/06/2026

Locations

Countries of recruitment

Sweden

Study participating centre
Skånes Universitetssjukhus
Department of Urology
Jan Waldenströms gata 7
Malmö
Sweden
205 02

Sponsor information

Organisation
Skåne University Hospital

ROR
<https://ror.org/02z31g829>

Funder(s)

Funder type
Government

Funder Name
Skåne Region Health Care Fund for Development and Innovation

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated in the present study will not be stored in a publicly available repository due to the small study size and mainly descriptive data.

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Other publications	Prior feasibility study results	02/06/2023	17/09/2025	Yes	No